Ponsegromab for the Treatment of Cancer Cachexia
Among patients with cancer cachexia and elevated GDF-15 levels, the inhibition of GDF-15 with ponsegromab resulted in increased weight gain and overall activity level and reduced cachexia symptoms, findings that confirmed the role of GDF-15 as a driver of cachexia. (Funded by Pfizer; ClinicalTrials.gov number, NCT05546476.).
Authors
- Shannon L. Lubaczewski (ORCID: https://orcid.org/0009-0009-8786-5798)
- Eric Roeland (ORCID: https://orcid.org/0000-0002-3674-3573)
- Jeffrey Crawford
- Richard F. Dunne (ORCID: https://orcid.org/0000-0001-6608-660X)
- Tateaki Naito (ORCID: https://orcid.org/0000-0003-4047-2929)
- John D. Groarke (ORCID: https://orcid.org/0000-0002-5277-8696)
- Andrew Hendifar (ORCID: https://orcid.org/0000-0002-2079-9177)
- Michelle I. Rossulek (ORCID: https://orcid.org/0009-0002-4478-9501)
- Marie Fallon (ORCID: https://orcid.org/0000-0001-9214-0091)
- Ruolun Qiu (ORCID: https://orcid.org/0000-0002-4051-6680)
- Susie M. Collins (ORCID: https://orcid.org/0009-0003-8732-6133)
- Carrie A. Northcott (ORCID: https://orcid.org/0000-0002-0197-4144)
- Koichi Takayama
- Magdalena Harrington (ORCID: https://orcid.org/0009-0006-5193-2678)
- Aditi R. Saxena (ORCID: https://orcid.org/0000-0001-6017-1838)
- F. Işık Karahanoğlu (ORCID: https://orcid.org/0000-0002-9162-8367)
- Timothy R. Asmis
Institutions
- Edinburgh Cancer Research (GB)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1056/nejmoa2409515
- Citations
- 200
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 65.31
Funders
- Pfizer